Comparative Pharmacology
Head-to-head clinical analysis: COACTIN versus ERYZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COACTIN versus ERYZOLE.
COACTIN vs ERYZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Coactin (mecillinam) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding protein 2 (PBP2) in gram-negative bacteria, leading to the formation of spheroplasts and cell lysis.
Erythromycin acts by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step.
400 mg orally every 6-8 hours with a full glass of water.
Adults: 500 mg orally once daily for 3 consecutive days per month.
None Documented
None Documented
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function; prolonged to 2-6 hours in renal impairment; clinically requires frequent dosing or dose adjustment in renal failure.
Terminal elimination half-life is 4-6 hours in patients with normal renal function (creatinine clearance >60 mL/min). In severe renal impairment (CrCl <30 mL/min), half-life may extend to 12-18 hours.
Renal: approximately 70-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: less than 10% as metabolites and unchanged drug.
Renal excretion of unchanged drug accounts for approximately 75% of the dose; fecal elimination is about 20%, with the remainder as biliary metabolites.
Category C
Category C
Antibiotic Combination
Antibiotic Combination